Abstract
Relebactam inhibits Ambler class A and C β-lactamases. Imipenem/relebactam has completed one phase 3 clinical study of patients infected with imipenem-non-susceptible Gram-negative bacilli. Two more phase 3 clinical studies are in progress for the treatment of patients with hospital-acquired and ventilator-associated bacterial pneumonia, complicated intra-abdominal infections and complicated urinary tract infections. In the current study, clinical Pseudomonas aeruginosa isolates cultured by medical centre laboratories in seven geographic regions (Africa, Asia, Europe, Latin America, Middle East, USA/Canada, South Pacific) were tested for susceptibility to imipenem/relebactam and comparators. A total of 12170 isolates collected as part of the 2015-2016 Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program were tested using the Clinical and Laboratory Standards Institute (CLSI)-defined broth microdilution method. Relebactam was tested at a fixed concentration of 4μg/mL in combination with doubling dilutions of imipenem. Imipenem/relebactam MICs were interpreted using current CLSI breakpoints for imipenem. At the imipenem susceptible breakpoint (≤2μg/mL), imipenem/relebactam inhibited 90.8% of all P. aeruginosa isolates and 70.7% of multidrug-resistant (MDR) isolates (n=3708). Relebactam restored imipenem susceptibility to 70.3% (2656/3776) of imipenem-non-susceptible isolates and increased percent susceptibility to imipenem against isolates with ceftazidime-non-susceptible (by 35.2%), piperacillin/tazobactam-non-susceptible (by 36.6%), cefepime-non-susceptible (by 36.8%) and MDR (by 41.9%) phenotypes. Across the seven geographic regions studied, susceptibility to imipenem/relebactam ranged from 84.0% (Latin America) to 96.0% (South Pacific). Imipenem/relebactam could provide an important treatment option against infections with P. aeruginosa isolates that are non-susceptible to several currently available antipseudomonal β-lactams.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
